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Abstract  1 
 2 
Background: 3 
Isoniazid-resistant, rifampin-susceptible tuberculosis (INH-R TB) is the most common 4 
form of drug resistance, and is associated with significant rates of failure, relapse, and 5 
acquired rifampin resistance if treated with first-line anti-TB drugs.   6 
The aim of the study was to compare success, mortality and acquired rifampin resistance 7 
with:1) different durations of rifampin, ethambutol and pyrazinamide (REZ); 2) 8 
fluoroquinolone plus 6 months or more of REZ; 3) streptomycin plus a core regimen of 9 
REZ, in INH-R  pulmonary TB.   10 
  11 
Methods: 12 
Individual patient data was obtained from authors of studies included in a published 13 
systematic review on pulmonary INH-R TB, additional studies identified in an updated 14 
search up to February 2016, personal communications from the same authors, and from 15 
authors responding to an invitation at a WHO European regional Resistant TB surveillance 16 
meeting. Studies with regimens and outcomes known for INH-R TB individual patients 17 
were eligible; regardless of the number of patients if randomized trials (RCT); or at least 20 18 
subjects if a cohort study. Bias was assessed based on eight items.   Authors supplied de-19 
identified clinical, treatment and outcome information. The individual patient data meta-20 
analysis was performed with propensity score matched logistic regression to estimate 21 
adjusted odds ratios and risk differences of treatment success, death during treatment and 22 
acquired rifampin resistance.  23 
Findings:  24 
Individual patient data was requested from authors of 57 cohort studies and 17randomized 25 
trials with 8089 patients with INH-R TB. We received 33 data sets with 6424 patients (27 26 
cohorts and 6 RCT), of which 3923 patients in 23 studies (21 cohorts and 2 RCT) received 27 
regimens related to the study objectives. When compared to a daily regimen of 6 months of 28 
rifampin, pyrazinamide and ethambutol, with or without isoniazid (6(H)REZ), extending 29 
the duration to 8-9 months had similar outcomes, hence >6(H)REZ was used for 30 
subsequent comparisons. Addition of a fluoroquinolone to >6(H)REZ was associated with 31 
significantly greater treatment success (aOR: 2·8, 95% CI: 1·1, 7·3), and non-significantly 32 
lower mortality (aOR: 0·7, 95% CI: 0·4, 1·1) and acquired rifampin resistance (aOR: 0·1, 33 
95% CI: 0·0, 1·2). When compared to >6(H)REZ, the standardized retreatment regimen (2 34 
months streptomycin, 3 months pyrazinamide and 8 months isoniazid, rifampin plus 35 
ethambutol) was associated with significantly worse treatment success (aOR: 0·4  95% CI: 36 
0·2, 0·7).  37 
Interpretation: 38 
In patients with INH-R TB, compared to treatment with at least 6 months of daily REZ, 39 
addition of a fluoroquinolone was associated with better treatment success, while addition 40 
of streptomycin was associated with less treatment success. Although this study utilised a 41 
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large number of patients with isoniazid-mono or poly resistance, with known individual 1 
characteristics, the quality of the evidence is very low, given the observational nature of 2 
most of the data, the diverse settings and the imprecision of estimates. These results 3 
support the conduct of randomized trials to identify the optimal regimen for this important 4 
and common form of drug-resistant TB. 5 
 6 
Funding:  7 
World Health Organization and Canadian Institutes of Health Research.  8 
 9 
  10 
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Introduction   1 
 2 
One of several major challenges impeding global tuberculosis (TB) control is the steady 3 
increase in the prevalence and severity of drug resistance.1 The World Health Organization 4 
(WHO) has estimated that 17% of isolates from patients newly diagnosed with TB have 5 
some form of drug resistance.2  Globally, the most common form of drug-resistant TB is 6 
isoniazid-resistant, rifampin-susceptible TB (INH-R TB) – estimated to account for 8% of 7 
all new cases.3 In most low and middle-income countries, access to drug susceptibility 8 
testing (DST) is very limited, so both new and previously treated patients receive 9 
standardized regimens with first-line TB drugs. The expanded access to Xpert ® MTB/Rif, 10 
means that INH-R TB will continue to be missed as this test does not identify the mutations 11 
(in KatG and INHa)4 associated with INH-R TB. A recent systematic review estimated that 12 
treatment of patients with unrecognized INH-R TB with the standard regimen 13 
recommended for new cases5 would result in combined failure and relapse rates of 12-13% 14 
and 8% rate of acquired rifampin resistance.6   15 
 16 
Despite the frequent occurrence, and major impact on outcomes, there has been remarkably 17 
little research on therapy for INH-R TB. The last randomized trial specifically of INH-R 18 
TB was published more than 20 years ago; in that trial the best regimen, of three tested, had 19 
a combined failure and relapse rate exceeding 11%.7 The previously recommended 20 
“retreatment” regimen, designed to manage INH-R TB, was never tested in a randomized 21 
trial.8 Hence, the optimal regimen composition, particularly use of fluoroquinolones, and 22 
duration of treatment remains controversial.3,5,9-11 23 
 24 
We conducted an individual patient data (IPD) meta-analysis of the treatment of patients 25 
with INH-R TB, to address three main questions: 1. Optimal duration of daily regimen of 26 
rifampin, ethambutol and pyrazinamide (REZ); 2. Benefit of adding a fluoroquinolone (FQ) 27 
to 6 months or more of REZ (sub-question of the benefit of adding a FQ to a regimen with 28 
6 months or more of RE but only 1-3 months Z); 3. Benefit of adding streptomycin (SM) to 29 
a core regimen of 6 or more months of RE but only 1-3 months Z (essentially the regimen 30 
formerly recommended by WHO for retreatment). The benefit of including isoniazid in 31 
each of these regimens was also addressed. We assessed treatment success (cure or 32 
completion), death (from any cause) during treatment, failure or recurrence of disease after 33 
success, and acquired rifampin resistance.  34 
  35 
Methods: 36 
The study protocol is available from the authors upon request. 37 
Data sources 38 
All studies on INH-R TB, included in a systematic review completed in May 2016 and 39 
published in 20176 were considered eligible. We re-reviewed the 49 excluded studies, and 40 
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identified 20 which had been excluded because regimens were individualized, multiple 1 
regimens had been used without stratifying results by regimen, some extra-pulmonary TB 2 
cases were included, or outcomes for INH-R were mixed with other resistance patterns. We 3 
considered these studies might have suitable individual data, so wrote to these authors as 4 
well. Studies included in a review on INH-R TB in children12 were also eligible. We 5 
restricted this IPD to studies published after 1990 because it was unlikely that any study 6 
would have used fluoroquinolones – one of our main objectives. We identified seven 7 
additional studies published after May 2015 through an updated search up to February 10th 8 
2016, using the same search terms and databases as the original review.6 Five of the 9 
contacted authors provided additional unpublished datasets; three have since been 10 
published.13-15 Three regional or national surveillance datasets were provided by those 11 
responding to an invitation to all participants at a WHO European regional Resistant TB 12 
surveillance meeting.16-18  13 
 14 
Specific criteria for participation in this IPD were: the study authors agreed to share their 15 
data, regimens and outcomes were known for individual patients, and at least 20 subjects 16 
were treated for INH-R TB if a cohort study. Randomized trials that included patients with 17 
INH-R TB were eligible regardless of the number of patients. Authors that agreed to share 18 
data signed formal data-sharing agreements. We excluded patients who did not receive any 19 
of the regimens specified by the study objectives.  20 
 21 
De-identified patient level information was obtained from an on-line data-sharing platform 22 
(Platform for Aggregations of Clinical TB Studies initiative19) for two studies, and directly 23 
from the authors for the remainder. This included: demographic data, clinical 24 
characteristics (comorbidities including HIV, site and extent of TB disease, results of chest 25 
radiography, and smear microscopy), and pre-treatment DST. Treatment information 26 
included drugs given, duration, end of treatment outcomes, and adverse events. 27 
Individualized regimens were tailored to individual patients’ characteristics, and DST 28 
results. Center-level information included: diagnostic laboratory methods, usual treatment 29 
doses and supervision, and treatment outcome definitions. Relapse was defined as any 30 
recurrence of disease within two years after successful treatment.  In studies which 31 
distinguished re-infection from relapse using molecular methods, re-infections were 32 
excluded.20   33 
  34 
Variables from each dataset were mapped to a common set of variables for all patients, and 35 
to verify, the clinical characteristics of each study population were compared with 36 
description of these characteristics in the published papers.  37 
 38 
Quality assessment 39 
As the studies in the IPD were mainly observational, we assessed bias and quality using 40 
eight items. Two were critical (sampling method and outcome definition) and six were 41 
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important criteria (participation rate, attrition rate and completeness of information for age, 1 
HIV status, cavity at chest-x ray and smear).  2 
Studies of high quality met both critical criteria and at least four of the six important 3 
criteria (see supplement table S1E – for quality criteria and assessments). Studies of 4 
moderate quality met one of the two critical parameters and at least four of the important 5 
criteria, or two critical parameters and at least three of the important criteria. Remaining 6 
studies were considered of low quality. We assessed overall quality of the evidence from 7 
this IPD following GRADE criteria.22  8 
 9 
Data analysis: 10 
Isoniazid resistant TB (INH-R TB) was defined as TB due to isolates with phenotypic 11 
resistance to isoniazid, and susceptibility to rifampin, with or without additional resistance 12 
to pyrazinamide, ethambutol or streptomycin.  13 
 14 
We analyzed three outcomes: (i) treatment success (cure or treatment completion 20) 15 
compared to treatment failure or relapse combined; (ii) acquired rifampin resistance among 16 
patients with failure or relapse; and, (iii) death from any cause during TB treatment – 17 
compared to success or failure/relapse. All analyses excluded patients who failed to 18 
complete treatment because of patient decision, or their outcomes were unknown (lost 19 
contact with patient, transfer out or other). The outcome of adverse events from anti-TB 20 
drugs could not be analyzed, as this was either not reported, or reported with very different 21 
definitions. 22 
 23 
For individualized regimens, the actual duration was estimated from dates when drugs were 24 
started and stopped. For standardized regimens, or randomized trials, if actual treatment 25 
duration was not available, the planned duration was used. For the outcome of death, which 26 
could occur at any time during treatment, duration could not be analyzed, since the duration 27 
of therapy was determined by the outcome. However, the analysis of mortality was 28 
restricted to the same data sets used for the analysis of treatment success – ie studies in 29 
which the regimens used and durations of regimens corresponded to the study questions.  30 
 31 
We used propensity score matching 23 (Caliper method with difference of 0·02 allowed, 1:1 32 
matching with replacement) based on age, gender, HIV co-infection, AFB smear, past 33 
history of TB treatment and resistance to other first line drugs, if the drug was used.  34 
We used a random effects (random intercept and random slope for matched pairs) model 35 
(using Proc GLIMMIX in SAS) to estimate adjusted odds ratios (aOR) and 95% confidence 36 
intervals (CI) of the three outcomes. Risk differences were calculated with fixed effects 37 
generalized linear models with identity link, adjusted for the propensity score. To test for 38 
heterogeneity of effect across studies, we used a generalized linear mixed model with an 39 
simulation-based approach specifically for individual patients data meta-analysis, to 40 
calculate the I2 statistic.24 41 
 42 
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For all outcomes and all questions, we performed the following sensitivity analyses: (i) 1 
restricting to the sub-group of patients who had not received isoniazid; (ii) restricting to the 2 
sub-group with cavitation on chest radiography; (iii) stratified by country income level 3 
(high, or low-middle); and, for the fluoroquinolone questions: (iv) restricting to patients 4 
who received levofloxacin or moxifloxacin. All analysis was performed using SAS, version 5 
9·4 (SAS Institute, Carey, N.C.).   6 
 7 
Ethical considerations:  8 
This project was approved by an ethics committee of the MUHC Research Institute (14274-9 
BMB) and by local ethical review boards when necessary.   10 
 11 
Role of the funding sources: 12 
Funding was received from the World Health Organization, as part of support from 13 
USAID. Funding was also received from the Canadian Institutes of Health Research 14 
(Foundation grant 143350). The funding sources had no role in the preparation of the 15 
manuscript, nor decision to publish. 16 
 17 
Results 18 
 19 
Study selection and description: 20 
As seen in figure 1, 74 studies  (57 observational studies and 17 RCT) were identified as 21 
potentially eligible, with an expected population of 8089 patients with INH-R TB. We 22 
received 33 datasets (27 from observational studies and 6 from RCT) with adequate 23 
treatment and outcome information for 5502 patients with pulmonary INH-R TB. In 10 24 
datasets, with 762 patients, no patients received any of the regimens of interest;13,25-33 in the 25 
remaining 23 datasets, 3923 patients14-18,34-52  received one of the regimens of the study 26 
questions, and 817 patients received other regimens. The characteristics of the patients 27 
from the 23 centers are summarized in table S1a. 15 studies contributed data for the 28 
question of duration of (H)REZ,14,16-18,34-36,38,40,42-45,47,50 15 studies for the question of 29 
addition of a fluoroquinolone to (H)REZ,14,17,18,34-36,38,40,42-45,47,50,52 15 studies to the related 30 
question of a FQ plus only 1-3 months of pyrazinamide,14,17,18,34-36,38,40,42-45,47,50,52  and all 31 
23 studies for the question of addition of streptomycin.14-18,34-52 The characteristics of the 32 
populations compared in each of the main analyses are summarized in appendix tables S3-33 
S6 (see also below). The regimens received by the 817 excluded patients from these centres 34 
are listed in table S1b. This included 139 patients who received high-dose isoniazid 35 
(450mg per day or more) – who could not be analyzed as they received several 36 
accompanying regimens. The characteristics of the 762 patients in the 10 studies where all 37 
patients were excluded are summarized in table S2a, and their treatment regimens in table 38 
S2b.  39 
 40 
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To define isoniazid resistance, a critical concentration of 0·1 or 0·2 mcg/ml was used by 21 1 
centers, and 0·25mcg/ml, or either 0·2 or 1·0 mcg/ml in single studies. The outcome 2 
definitions and drug dosages given were in accordance with WHO guidelines (tables S1c 3 
and S1d). Daily regimens were used in all but one study.50 Therapy was directly supervised 4 
throughout treatment for 2018 patients in 14 centres. Actual duration of therapy was known 5 
in 16 studies (2422 participants, of whom duration was not known in 15), and planned 6 
duration in the remaining 7 studies (1513 persons). Overall, 345 of all 3923 patients (9%) 7 
were lost, or transferred out without known outcome, or stopped therapy for patient 8 
decision. In 19 of 23 studies recurrence/relapse was measured, during follow-up that 9 
exceeded one year in about two-thirds of patients; only two of these centers34,39 used 10 
molecular methods to identify reinfection. Quality assessments are summarized in appendix 11 
table S1E; based on the criteria selected, the quality was judged low in one study, moderate 12 
in four, and high in the remainder. 13 
Results of testing for heterogeneity (i.e. estimated I squared, using a generalized linear 14 
mixed model adjusted for the same confounding factors used in the propensity score 15 
matching) are presented for each analysis in tables 1-4. In general, for analyses in which I 16 
squared was estimable, the heterogeneity was low (<50%).  17 
The analyzed population included only 37 children, 119 patients with diabetes mellitus, and 18 
249 with HIV infection with or without antiretroviral treatment; these small numbers 19 
precluded separate analyses, for any study questions, within these sub-groups.  20 
 21 
Question 1: Duration of (H)REZ 22 
 23 
As seen in table S3, patients receiving 6 months (H)REZ were older, more likely treated in 24 
high income countries and less likely to be acid fast bacilli (AFB) smear-positive than 25 
patients receiving more than 6 months (H)REZ. 26 
 27 
As seen in table 1, odds of success were non-significantly higher with the six month 28 
regimen (aOR 2·4; 95%CI 1·0; 5·5), and acquired resistance was non-significantly lower 29 
(aOR 0·2; 95%CI 0·0; 1·7). When patients taking isoniazid (at usual doses) for at least one 30 
month were excluded (table 1) outcomes were similar. Hence, we combined all individuals 31 
who received 6 or more months of REZ, with or without isoniazid (usual doses) as the 32 
comparator group for all analyses.  33 
 34 
Question 2: Use of a Fluoroquinolone. 35 
 36 
In total, 251 patients received a FQ for at least one month and at least 6 months of REZ, of 37 
whom 165 received a later generation FQ. Compared to those who received >6(H)REZ, 38 
clinical characteristics were very similar, except that 98% of those who received a FQ were 39 
treated in high income countries (table S4). 40 
 41 
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The 251 who received a FQ had significantly higher odds of treatment success than those 1 
who did not, and non-significantly lower odds of acquired resistance to rifampin and of 2 
mortality (table 2). Estimates of effect were similar, and non-significant, when restricting 3 
the analysis to the subgroup of patients who did not receive isoniazid, or patients who 4 
received only later generation FQ. 5 
 6 
Only 118 patients received a FQ together with 6 or more months of rifampin and 7 
ethambutol, and 1-3 months of pyrazinamide, of whom 105 received a later generation FQ. 8 
As seen in table S5, they were substantially older, and less likely to have cavitation or AFB 9 
positive smears than the comparison group. In these patients, use of a FQ was associated 10 
with non-significantly higher success, with similar results when restricting the analysis to 11 
use of a later generation FQ (table 3). Due to the small number of patients who received 12 
this regimen, the estimates of effect were very imprecise.  13 
 14 
Question 3: Use of Streptomycin. 15 
 16 
The 325 individuals who received the standardized retreatment regimen were more likely 17 
to have cavitary disease, poly-drug resistance, or previous TB treatment (reflecting the 18 
usual indication for this regimen), compared to the 1350 who received >6(H)REZ (table 19 
S6). 20 
  21 
As seen in table 4, the streptomycin-containing regimens were associated with significantly 22 
lower odds of success when all patients were considered, and non-significantly lower 23 
success when the analysis was restricted to patients who did not receive isoniazid. On the 24 
other hand, mortality was virtually identical in patients who did, or did not receive 25 
streptomycin, in analyses with, and without, patients receiving isoniazid. There were 26 
insufficient numbers to analyse acquired rifampin resistance. 27 
 28 
Sensitivity analyses: 29 
There were very few studies from low-middle income countries for the question of REZ 30 
duration, fluoroquinolones were predominantly used in centres in high income countries, 31 
while Streptomycin was used almost exclusively in low-middle income countries – limiting 32 
these stratified analyses. As seen in appendix table S7, in analyses restricted to studies in 33 
high income countries, six months of REZ was associated with very similar outcomes as 34 
the longer duration of REZ, and addition of a FQ was associated with non-significantly 35 
better success. When analyses were restricted to low income countries (appendix table S8), 36 
streptomycin containing regimens had non-significantly lower success and higher 37 
mortality.  38 
 39 
When analyses were restricted to patients with cavitation on chest radiography (appendix 40 
table S9) there was no evidence that addition of FQ or SM was more or less beneficial than 41 
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in the primary analyses. Finally, the duration of FQ did not appear to be a determinant of 1 
success (appendix table S10). 2 
 3 
Overall quality of evidence: 4 
Even though most studies were considered high quality, we considered that the risk of bias 5 
was high, given that all but two were observational, and most provided individualized 6 
treatment. Because relatively small numbers of patients received the regimens of interest, 7 
estimates of effect were generally imprecise with wide confidence intervals. There were 8 
also concerns over directness – for the findings of FQ to low-middle income settings, and 9 
for the SM analyses to high income settings. Hence, overall the evidence from this IPD 10 
should be considered of very low quality.  11 
 12 
Discussion 13 
We assembled a large set of individual data of patients with INH-R TB, mostly from 14 
observational studies. This study fills an important knowledge gap on the relative efficacy 15 
of different regimens to treat INH-R-TB. Compared to a ‘core’ regimen containing REZ, 16 
addition of a FQ was associated with significantly higher odds of success, while a treatment 17 
regimen with SM added in the first months of treatment and shorter Z (the ‘retreatment 18 
regimen’) was associated with worse results. 19 
 20 
This study had a number of important strengths. Individual data for a large number of 21 
patients with isoniazid-mono or poly resistance was assembled. Treatment outcomes were 22 
defined according to published recommendations.20 Data was contributed from 23 centers 23 
in 18 countries from a wide range of resource levels, enhancing generalizability of results. 24 
Having individual patient data meant we could adjust for measured confounding patient 25 
characteristics such as age, prior treatment, HIV, sputum smear and additional resistance. 26 
 27 
Nevertheless, the study had also important limitations. Despite extensive efforts to 28 
assemble the largest possible number of patients treated for INH-R TB, the numbers of 29 
patients who received certain regimens of interest, such as the FQ with only 1 to 3 months 30 
pyrazinamide, were very small, providing limited power, or, as was the case with high dose 31 
INH, simply too few to perform any analyses. Lab methods were not standardized across 32 
centres, and while most centres used the same critical concentration, other differences in 33 
lab methods may have contributed to between centre differences in outcomes, resulting in 34 
reduced precision. All studies used phenotypic methods to perform DST – which may 35 
underestimate rifampin resistance, and could have affected results.53 Relapse may have 36 
been over-estimated, as this was distinguished from re-infection using molecular methods 37 
in only two of the 19 studies that reported recurrence. We did not include those lost to 38 
follow-up (during treatment) in any analysis due to their uncertain outcomes; fortunately, 39 
this accounted for less than 9% of all patients in the 23 studies (table S1a). 40 
 41 
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All but two50,51 of the 23 studies included in the analyses were observational. Ten used 1 
individualized regimens, which may lead to confounding by indication as sicker patients 2 
may have been more, or less likely to receive certain drugs or durations. The most 3 
important limitation is that the regimens used, particularly use of SM or FQ, may have been 4 
confounded with differences in patient or centre characteristics – such as country income 5 
level. Despite adjusting for individual-level characteristics, residual confounding may have 6 
occurred due to unmeasured differences in patient characteristics such as nutritional status. 7 
As well treatment given at different centres may have been confounded with differences 8 
between centres, such as resources available for patient support. To account for this, we 9 
performed sensitivity analyses restricted to studies from high-income or low-middle 10 
income countries only. For most of these analyses, estimates of effect were similar, but less 11 
precise, due to fewer studies and patients included (tables S7 and S8).  12 
 13 
Additional limitations were the small number of children, HIV-infected patients, and 14 
patients with diabetes– limiting generalizability to these important groups of patients. Less 15 
than half the studies reported acquired rifampin resistance during treatment; the resulting 16 
smaller numbers limit our inferences for this outcome. The impact of treatment duration on 17 
mortality could not be assessed as duration of therapy was truncated by death. A final 18 
limitation was that adverse drug reactions could not be analyzed, as planned, because these 19 
were not reported, or reported using widely varying definitions, methods of investigation, 20 
and management. Non-standardized reporting of adverse events in the treatment of drug-21 
resistant TB has been noted in other reviews of drug-resistant TB treatment.54,55  22 
 23 
The study has several important implications for treatment of INH-R TB or of patients in 24 
whom INH cannot be used. First, these findings emphasize the importance of detecting this 25 
form of drug resistance. Secondly, the regimen of 6 months REZ provides good results in 26 
patients with INH-R TB; more than 6 months of this regimen was not associated with 27 
improved outcomes, except in participants with cavitation, in whom there was a non-28 
significant trend to better outcomes with the longer duration. This study provides evidence 29 
of benefit from adding a FQ to a core regimen that includes REZ, although the optimal 30 
duration and specific type of FQ have not been clarified. Given that pyrazinamide is the 31 
most toxic of the current first-line drugs,56 the major advantage of adding a FQ would be if 32 
pyrazinamide could be reduced to the initial two months. Because of the small number of 33 
patients who received this regimen the imprecision of results precludes firm conclusions, 34 
but the promising results motivate further evaluation. An additional implication of this 35 
study is that the standardized retreatment regimen8 appears to be of limited benefit in 36 
patients with confirmed INH-R TB. A final treatment implication is that isoniazid at 37 
normal doses is of minimal benefit in patients with INH-R TB, even when the low critical 38 
concentration of 0·1-0·25 mcg/ml was used to define resistance with DST. Response to 39 
treatment may vary according to genotypic forms of isoniazid-resistance;57 hence complete 40 
genotypic information would be informative in future studies.  41 
 42 
IPD-MA of Treatment of isoniazid Resistant Tuberculosis 
Manuscript accepted for publication by the Lancet Respiratory Medicine 14 
We conclude that, for the treatment of INH-R TB, addition of a FQ to a core regimen of 6 1 
months of daily REZ provides optimal outcomes, although we could not define the best 2 
FQ, nor the optimal duration of FQ nor pyrazinamide. Addition of isoniazid, and 3 
prolongation of daily REZ beyond 6 months appear to provide no benefits. Addition of 4 
streptomycin, and in particular the streptomycin-containing previously recommended 5 
retreatment regimen, was associated with significantly worse treatment success. These 6 
results, based on observational data, must be considered very low-quality evidence, and so 7 
are insufficient to support strong treatment recommendations. However, they do strongly 8 
support the conduct of randomized trials to identify the optimal regimen for this important 9 
and common form of drug-resistant TB. 10 
 11 
 12 
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Evidence before this study:  46 
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Drug resistant tuberculosis is one of the major challenges impeding global tuberculosis 1 
(TB) control. Isoniazid-resistant, rifampin-susceptible TB (INH-R TB) is the most common 2 
form of drug-resistant TB. In settings were drug susceptibility testing is not accessible or 3 
there is access only to Xpert ® MTB/Rif, INH-R TB will be missed, and treated with 4 
standard regimens. Despite the frequent occurrence of INH-R TB and its major impact on 5 
outcomes, there has been remarkably little research on therapy for INH-R TB. Hence, the 6 
optimal regimen for INH-R TB, including use of fluoroquinolones and duration of 7 
treatment remains controversial. 8 
This IPD meta-analysis was built upon a recent systematic review and aggregate data meta-9 
analysis (Gegia el at., Lancet Infect Dis. 2017; 17(2):223-34), in which four electronic 10 
databases (Cochrane database of systematic reviews and randomized trials, PubMed, 11 
Embase and HealthStar) were searched with the terms “Tuberculosis” AND “treatment” 12 
OR “therapy” AND “INH” OR “isoniazid resistance” up to March 2015.   This  review 13 
found that treatment of patients with unrecognized INH-R TB with the standard regimen 14 
recommended for newly diagnosed patients would result in combined failure and relapse 15 
rates of 12%, and 8% would acquire rifampin resistance.  All studies  included in this 16 
review were considered eligible for the IPD meta-analysis. We added previously excluded 17 
studies that might have been suitable for individual data analysis, plus studies included in a 18 
review on INH-R TB in children, and seven additional studies published after May 2015 19 
identified from an updated search finalized on February 10th 2016, using the same search 20 
terms and databases as the original review. In addition, five of the contacted authors 21 
provided other  unpublished datasets (three now published) and three regional or national 22 
surveillance datasets were provided by authors responding to an invitation to all 23 
participants at a WHO European regional Resistant TB surveillance meeting.  24 
 25 
Added value of this study:  26 
Subject-level data were compiled from 33 studies and a total of 3923 patients from 23 of 27 
these studies (21 cohorts and 2 randomized clinical trials), received one of the regimens of 28 
interest. Bias was assessed by using an eight items scale: sampling method and outcome 29 
definition were critical and six were important criteria (participation rate, attrition rate and 30 
completeness of information for age, HIV status, cavity at chest-x ray and smear). Based on 31 
these criteria, the quality was judged low in one study, moderate in four, and high in the 32 
remainder. 33 
Compared to 6 months of rifampin, ethambutol and pyrazinamide (REZ), longer duration 34 
of REZ did not results in significantly improved treatment success or less acquired drug 35 
resistance. Addition of a fluoroquinolone to a core regimen of at least 6 months of REZ, 36 
was associated with improved success, and less acquired drug resistance, but no difference 37 
in mortality. Adding an FQ to a regimen with 2-3 months Z, and 6 or more months of R&E, 38 
resulted in somewhat, but not significantly, better odds of success. The retreatment regimen 39 
(SM added to 6 months of RE and 1-3 months of Z) was associated with significantly 40 
worse success, compared to at least 6 months REZ.  41 
 42 
Implications of all the available evidence: 43 
Findings of this study emphasize the importance of detecting INH resistance and support 44 
the use of FQ in addition to a core regimen of 6 months of REZ. The addition of isoniazid, 45 
and prolongation of REZ beyond 6 months appear to provide no benefits for this condition. 46 
Our results support a move away from use of the streptomycin-containing previously 47 
recommended retreatment regimen. Because of the observational nature of the data, these 48 
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results are graded very low quality evidence; hence these results are insufficient to support 1 
strong treatment recommendations. But they do support the conduct of randomized trials to 2 
define the optimal treatment of this common and overlooked condition – particularly to 3 
assess the optimal type and duration of FQ and optimal duration of pyrazinamide. 4 
 5 
 6 
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Tables  1 
 2 
Table 1: Comparison of 6(H)REZ vs >6(H)REZ: Treatment success and acquired rifampin resistance.  3 
 4 
Outcome  
Regimens:  
 
N datasets 
included 
N events/ N 
on treatment 
I 
squaredd 
N pairs 
useda 
from Propensity Score matched Analysisb 
aOR (95% CI) 
Risk Difference (per 1,000 treated with 
95%CI) 
Analyses in all patients  (with or without 
isoniazid) 
  
  
  
Success 
6(H)REZ   15 254/262 NCe 262 2·4 (1·0; 5·5) 
40 more per 1,000 
(from 0 difference to 80 more) 
>6(H)REZ    999/1088   1 (reference) (reference) 
Acquired rifampin 
resistance 
6(H)REZ   10 1/168c NCe 168 0·2 (0·0; 1·7) 
 10 fewer per 1,000 (from 60 fewer to 40 
more) 
>6(H)REZ    43/992c   1 (reference) (reference) 
Patients who received isoniazid excluded       
Success 
6REZ   13 136/142 36% 140 2·5 (0·9; 7·5) 
50 more per 1,000 (from 10 fewer to 100 
more) 
>6REZ    701/785   1 (reference) (reference) 
Acquired rifampin 
resistance 
6REZ   8 0/84 NCe 84 not estimable not estimable 
>6REZ    43/729   1 (reference) (reference) 
 5 
Notes:  6 
a) Number of pairs used in propensity score matched analysis. For example, 262 persons who received 6(H)REZ and an equal number who received the comparator were analyzed for the 7 
outcome of success;   8 
b) Estimates based on pairs matched for age, sex, HIV status, past TB treatment, sputum AFB smear (positive vs negative) and resistance to other drugs besides isoniazid, if used. Percentage of 9 
patents missing information for these variables: past TB treatment: 8%; AFB smear: 2%; HIV 8%, polyresistance, age and sex: 0%. HIV status was missing, but assumed to be negative 10 
in 3 studies  (n =720 patients) in settings where the prevalence of HIV co-infection rate in patients with active TB was <5% based on WHO surveillance data. 11 
c) N treated is less than in success analysis because patients with fail/relapse but no acquired drug resistance or with non-rifampin acquired resistances were excluded from this analysis.  12 
d) I squared estimated for the adjusted odds ratios using a generalized linear mixed model with an simulation-based approach specifically for individual patients data meta-analysis.24 13 
e) NC: the I squared could not be calculated because the Tau squared (on which the I squared is based) was not estimated in SAS.    14 
Abbreviations: aOR: adjusted odds ratio;  CI Confidence interval E: ethambutol; (H)= isoniazid used in some, but not all regimens  SM: streptomycin;  R: rifampin; Z: pyrazinamide.  15 
 16 
 17 
18 
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 Table 2. Association of use of fluoroquinolones with treatment success, mortality and acquired rifampin resistance.  1 
Outcome  
Regimens:  
FQ 
Comparator 
N datasets 
included 
N events/ N on 
treatment 
I squarede 
N pairs 
usedc 
from Propensity Score matched Analysisd 
aOR (95% CI) 
Risk Difference (per 1,000 treated 
with 95%CI) 
Analyses in all patients   (with or without 
isoniazid) 
  
  
  
Mortality  (all durations) 
(H)REZ   FQ 15 25/524 12% 522 0·7 (0·4; 1·1) 
20 fewer per 1,000 
(from 50 fewer to 0 difference) 
(H)REZ   97/2174   1·0 (reference) (reference) 
Success 
≥6(H)REZ   FQ 15 245/251  36% 248 2·8 (1·1 to 7·3) 
50 more per 1,000 
(from 0 difference to 90  more) 
≥6(H)REZ    1253/1350    1·0 (reference) (reference) 
Success (restricted to later 
generation FQ- 
Moxi/Levo/Gati)  
≥6(H)REZ   FQ 15 161/165a 44% 164 2·9 (0·9 to 9·3) 
60 more per 1,000  
(from 20 fewer to 140 more) 
≥6(H)REZ    1253/1350    1·0 (reference) (reference) 
Acquired rifampin 
resistance 
≥6(H)REZ   FQ 10 1/221b  2%f 220 0·1 (0·0 to 1·2) 
30 fewer  per 1,000  
(from 60 fewer to 0 difference) 
≥6(H)REZ   44/1160b    1·0 (reference) (reference) 
Patients who received isoniazid excluded       
Mortality 
REZ   FQ 14 8/219 0 205 0·4 (0·2 to 1·1) 
20 fewer per 1,000  
(from 60 fewer to 20 more) 
REZ    41/1054   1·0 (reference) (reference) 
Success 
≥6REZ   FQ 14 131/135 33% 127 5·4 (1·8 to 16·6) 
130 more per 1,000  
(from 40 fewer to 230 more) 
≥6REZ  837/927   1·0 (reference) (reference) 
Acquired rifampin 
resistance 
≥6REZ   FQ 9 1/111  NCe 107 0·1 (0·0 to 1·0) 70 fewer (140 fewer to 0 difference) 
≥6REZ   43/813   1·0 (reference) (reference) 
 2 
Notes:  3 
a) Of the 165 treated, 67 received isoniazid for one month or more and 98 did not receive any Isoniazid;   b) Number treated is less than in success analysis because patients with 4 
fail/relapse but no acquired drug resistance or with non-rifampin acquired resistances were excluded from this analysis.     c) Number of pairs used in propensity score matched analysis. 5 
For example 248 persons who received (H)REZFQ and an equal number who received the comparator were analyzed for the outcome of success;  d) Estimates based on pairs matched 6 
for age, sex, HIV status, past TB treatment, sputum AFB smear(positive vs negative) and resistance to other drugs besides ISONIAZID, if used. Percentage of patents missing 7 
information for these variables: past TB treatment: 8%; AFB smear: 8%; HIV 8%, polyresistance, age and sex: 0%. HIV was missing, but assumed to be negative in 3 studies (n=1164 8 
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patients) in settings where the prevalence of HIV coinfection rate in patients with active TB was <5%, based on WHO surveillance data.    e) I squared estimated for the adjusted odds 1 
ratios using a generalized linear mixed model with an simulation-based approach specifically for individual patients data meta-analysis24 NC:the I squared could not be calculated 2 
because the Tau squared (on which the I squared is based) was not estimated in SAS.   f) this is an unadjusted I squared value, adjusted could not be calculated 3 
 4 
Abbreviations: aOR: adjusted odds ratio; CI Confidence interval E: ethambutol; (H)= isoniazid used in some, but not all regimens  SM: streptomycin;  R: rifampin; Z: pyrazinamide; 5 
FQ: Fluoroquinolone.   6 
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 1 
 2 
 Table 3. Association of use of Fluoroquinolone with 1-3 months Pyrazinamide - with treatment success, and acquired rifampin resistance (i.e. Six months or 3 
more of RE plus 1-3 months of Z plus fluoroquinolone compared to 6 months or more of REZ - with or without isoniazid. Analyses not performed in patients who did 4 
not receive isoniazid because too few patients). 5 
Outcome Regimen 
N datasets 
included 
N events/N 
on treatment 
I squaredf 
N pairs 
used in 
matchingc 
aOR (95% CI) 
from Propensity 
Score matched 
Analysisd 
Risk Difference (per 1,000 
treated with 95%CI) 
Success (all FQ) 
≥(H)6RE  1-3Z FQ 15 117/118a NCf 108 5·2 (0·6 to 46·7) 
40 more per 1,000 
(from 20 fewer to 90 more) 
≥6(H)REZ   1253/1350b    1·0 (reference) (reference) 
Success - Restricted to 
later generation FQ 
(Moxi/Levo/Gati) 
≥6(H)RE  1-3Z FQ 15 104/105  NCf 97 5·2 (0·6 to 47·2) 
50 more per 1,000 
(from 30 less to 120 more) 
≥6R(H)EZ   1253/1350    1·0 (reference) (reference) 
Acquired RIF resistance 
≥6(H)RE  1-3Z FQ 10 0/113e  NCf -- not estimable not estimable 
≥6(H)REZ    44/1160e    1·0 (reference) (reference) 
 6 
Notes:   7 
a) Of the 118 treated, 82 received isoniazid for one month or more and 36 did not receive isoniazid;  8 
b) Of the 1350 treated, 423 had isoniazid for one month or more and 927 did not;  9 
c) Number of pairs used in propensity score matched analysis. For example, 108 persons who received ≥(H)6RE(1-3)ZFQ and an equal number who received the comparator were 10 
analyzed for the outcome of success;   11 
d) Estimates based on pairs matched for age, sex, HIV status, past TB treatment, sputum AFB smear (positive vs negative) and resistance to other drugs besides ISONIAZID, if used. 12 
Percentage of patents missing information for these variables: past TB treatment: 8%; AFB smear: 3%; HIV 10%, polyresistance, age and sex: 0%. HIV was missing, but assumed to be 13 
negative in 3 studies (n=738 patients) in settings where the prevalence of HIV coinfection rate in active TB patients was <5% based on WHO surveillance data. 14 
e) Number treated is less than in previous table because patients with fail/relapse but who did not acquired drug resistance or who acquired non-rifampin resistances were excluded from 15 
this analysis.  16 
f) I squared estimated for the adjusted odds ratios using a generalized linear mixed model with an simulation-based approach specifically for individual patients data meta-analysis24.  17 
NC:the I squared could not be calculated because the Tau squared (on which the I squared is based) was not estimated in SAS.    18 
Abbreviations: aOR: adjusted odds ratio;  CI Confidence interval E: ethambutol; (H)= isoniazid used in some, but not all regimens  SM: streptomycin;  R: rifampin; Z: pyrazinamide;  19 
FQ: Fluoroquinolone; .  20 
 21 
 22 
 23 
  24 
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Table 4. Association of use of streptomycin with treatment success, mortality and acquired rifampin resistance.  (Note: analysis of acquired rifampin resistance 2 
not performed in patients who did not receive isoniazid because too few patients).  3 
Outcome 
Regimens 
SM containing 
Comparator 
N datasets 
included 
N events/N 
on treatment 
I 
squarede 
N pairs 
useda  
from Propensity Score matched Analysisb 
aOR (95% CI) 
Risk Difference (per 1,000 treated 
with 95%CI) 
Analyses done in all patients  (with or without isoniazid)      
Mortality  (all 
durations) 
6(H)REZ + SM 23 40/763  14% 756 0·9  (0·6 to 1·3) 
10 fewer per 1,000 
(from 30 fewer to 20 more) 
6(H)REZ   103/2263   1·0 (reference) (reference) 
Success  
≥6(H)RE 1-3Z  2SM 23 271/325  0 296 0·4 (0·2 to 0·7) 
120 fewer per 1,000 
(from 190 fewer to 60 fewer) 
≥6(H)REZ    1253/1350   1·0 (reference) (reference) 
Acquired RIF 
resistance 
≥6(H)RE 1-3Z   2SM 14 6/58c  NCE -- not estimabled -- 
≥6(H)REZ   44/1160c   1·0 (reference) (reference) 
Patients who received isoniazid excluded      
Mortality 
REZ  + SM 14 6/136 NCE 133 1·2 (0·4 to 4·1) 
0 difference per 1,000 
(from 50 fewer to 60 more) 
REZ    41/1054   1·0 (reference)  
Success 
≥6RE 1-3Z 2SM 14 89/107 NCE 105 0·5 (0·2 to 1·2) 
80 fewer per 1,000 
(from 170 fewer to 10 more) 
≥6REZ    837/927   1·0 (reference) (reference) 
 4 
Notes: 5 
a) Number of pairs used in propensity score matched analysis. For example, 296 persons who received 6(H)REZ + SM and an equal number who received the comparator were 6 
analyzed for the outcome of success;    7 
b) Estimates based on pairs matched for age, sex, HIV, past TB treatment, sputum AFB smear (positive vs negative) and resistance to other drugs besides isoniazid, if used. Percentage 8 
of patents missing information for these variables: past TB treatment: 12%; AFB smear: 7%; HIV 7%, polyresistance: 2%, age: 1%, sex: 1%. HIV was missing, but assumed to be 9 
negative in 6 studies (n=1389 patients) in settings where the prevalence of HIV co-infection rate in active TB patients was <5% based on WHO surveillance data 10 
 c) Number treated is less than in success analysis because patients with fail/relapse but without acquired drug resistance or with non-rifampin acquired resistances were excluded from 11 
this analysis;  12 
d) Propensity score matching models did not converge.  13 
e) I squared estimated for the adjusted odds ratios using a generalized linear mixed model with an simulation-based approach specifically for individual patients data meta-analysis24.  14 
NC: the I squared could not be calculated because the Tau squared (on which the I squared is based) was not estimated in SAS.    15 
Abbreviations: aOR: adjusted odds ratio; CI Confidence interval E: ethambutol; (H)= isoniazid used in some, but not all regimens  SM: streptomycin;  R: rifampin; Z: pyrazinamide 16 
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